Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:1481-1487
Published online before print April 27, 2006, doi: 10.1161/01.ATV.0000223875.14120.93
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
26/7/1481    most recent
01.ATV.0000223875.14120.93v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liou, J.-Y.
Right arrow Articles by Wu, K. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liou, J.-Y.
Right arrow Articles by Wu, K. K.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:1481.)
© 2006 American Heart Association, Inc.


Vascular Biology

Protection of Endothelial Survival by Peroxisome Proliferator-Activated Receptor-{delta} Mediated 14-3-3 Upregulation

Jun-Yang Liou; Sang Lee; Dipak Ghelani; Nevenka Matijevic-Aleksic; Kenneth K. Wu

From the Vascular Biology Research Center (J.-Y.L., S.L., D.G., K.K.W.), Brown Foundation Institute of Molecular Medicine, and Division of Hematology (J.-Y.L., S.L., D.G., N.M.-A., K.K.W.), Department of Internal Medicine, Medical School, University of Texas Health Science Center at Houston.

Correspondence to Kenneth K. Wu, Vascular Biology Research Center, Brown Foundation Institute of Molecular Medicine, and Division of Hematology, Department of Internal Medicine, Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030-1503. E-mail kenneth.k.wu{at}uth.tmc.edu

Objective— To determine the role of prostacyclin (PGI2) in protecting endothelial cells (ECs) from apoptosis and elucidate the protective mechanism.

Methods and Results— To evaluate the effect of PGI2 on EC survival, we treated ECs with Ad-COX1/PGIS (Ad-COPI), which augmented selectively PGI2 production or carbaprostacyclin (cPGI2) followed by H2O2 for 4 hours. Ad-COPI inhibited annexin V–positive cells and blocked caspase 3 activation. cPGI2 inhibited apoptosis in a concentration-dependent manner. L-165041 had a similar effect, suggesting the involvement of peroxisome proliferator-activated receptor-{delta} (PPAR{delta}). ECs expressed functional PPAR{delta}. PPAR{delta} overexpression enhanced whereas PPAR{delta} knockdown by small interfering RNA abrogated the antiapoptotic action of cPGI2 and L-165041. Our results show for the first time that PGI2 stimulated 14-3-3{alpha} expression via PPAR{delta} activation. cPGI2 and L-165041 induced binding oaf PPAR{delta} to PPAR response elements located between –1426 and –1477 of 14-3-3{alpha} promoter region, thereby activating 14-3-3{alpha} promoter activity and protein expression. Upregulation of 14-3-3{alpha} proteins resulted in an increase in Bad binding to 14-3-3{alpha} and a reduction in Bad translocation to mitochondria.

Conclusions— PGI2 protects ECs from H2O2-induced apoptosis by inducing PPAR{delta} binding to 14-3-3{alpha} promoter, thereby upregulating 14-3-3{alpha} protein expression. Elevated 14-3-3{alpha} augments Bad sequestration and prevents Bad-triggered apoptosis.

We postulated that EC-synthesized PGI2 protects ECs from apoptosis. Results show that PGI2 generated by transduction with an adenoviral vector containing a bicistronic cyclooxygenase-1 and PGI2 synthase construct (Ad-COPI) or synthetic carbaprostacyclin (cPGI2) suppressed H2O2-induced EC apoptosis by a novel PPAR{delta}-mediated 14-3-3{alpha} transcriptional upregulation.


Key Words: apoptosis • endothelial cells • PPAR{delta}, prostacyclin • 14-3-3